AstraZeneca published a semi‑automated liquid chromatography‑mass spectrometry (LC‑MS) workflow designed to accelerate and standardize oligonucleotide analytical characterization, aiming to reduce late‑stage failures in oligo drug discovery. The dual screening platform streamlines analysis across hundreds to thousands of oligos at early discovery stages. Led by Kathrin Stavenhagen, the team described a scalable dual workflow that integrates rapid screening and detailed characterization to replace labor‑intensive lab‑developed tests. AstraZeneca framed the platform as a response to surging demand in the oligonucleotide therapeutics market and manufacturing scale‑up challenges. For oligo developers and CMOs, the method promises faster CMC cycles and improved triage of candidates heading toward in vivo testing. The publication signals industrial investment in analytics as a critical bottleneck solution for the growing ASO/siRNA/oligonucleotide pipeline.